Navigation Links
Study Weighs Cost, Benefit of Gene Tests Before Warfarin Rx
Date:1/20/2009

The screens resulted in better patient outcomes but at high price, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Genetic testing isn't cost-effective in guiding initial dosing of the blood thinner warfarin in patients with atrial fibrillation (a type of abnormal heart rhythm), a University of Cincinnati study finds.

Warfarin is used to prevent blood clotting in these patients. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin to suggest that doctors consider genetic testing before using the blood thinner.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," study lead investigator Dr. Mark Eckman, professor of medicine, explained in a UC news release.

"The idea behind genetic testing -- also known as pharmacogenetic-guided dosing -- is to help guide the initial, and possibly lower, dose of warfarin for patients," Eckman said. "The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

He and his colleagues analyzed the findings of three published studies and then created a model to estimate the cost-effectiveness of genetic testing.

They found that genotype-guided dosing did result in better patient outcomes but at a cost of more than $170,000 per quality-adjusted life year gained. They also found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective. The findings were published in the Jan. 20 issue of the journal Annals of Internal Medicine.

The researchers concluded that genotype-guiding dosing is cost effective if it:

  • is used for patients at high risk for hemorrhage;
  • prevents more than 32 percent of major bleeding events;
  • is available within 24 hours;
  • costs less than $200.

"This could be accomplished if testing were done in-house, at lower cost and without delays," said Eckman. Currently, most of these tests have to be sent to outside laboratories, which can lead to increased cost and treatment delays.

More information

The U.S. Agency for Healthcare Research and Quality has more about warfarin.



-- Robert Preidt



SOURCE: University of Cincinnati, news release, Jan. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study compares 2 nonsurgical treatments for reflux disease
2. Study examines racial disparities in survival among patients diagnosed with lung cancer
3. Study shows rise in antibiotic resistant pediatric head and neck infections
4. Study: Growth in research comes at a steep price
5. National Childrens Study Begins Recruiting
6. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
7. Tufts receives NIH grant to study obesity prevention in new immigrants
8. New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage
9. 2009 Most Wired Survey and Benchmarking Study Opens Today
10. Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
11. Newer Antipsychotics Pose Cardiac Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Weighs Cost, Benefit of Gene Tests Before  Warfarin Rx
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Patients who ... to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. ... for a variety of treatments. One or more sedation methods may be recommended based ...
(Date:5/22/2017)... ... May 22, 2017 , ... “Homeostasis: The Journey of ... to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride that ... the dead of winter and to a dark place where Donald considers suicide. ...
(Date:5/22/2017)... IL (PRWEB) , ... May 22, 2017 , ... ... is part of a larger group investing in InsightRX, an early stage company ... patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel ... created specifically for use in Final Cut Pro X. The business-oriented elements and ... Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look to ...
(Date:5/21/2017)... Georgia (PRWEB) , ... May 21, 2017 , ... For ... designs that cover a wide range of knives and swords, from functional to fantasy. ... deliver the goods with sleek, modern designs that defy tradition. , Offering a range ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology: